Allurion Technologies Inc. reported preliminary, unaudited results for the fourth quarter and fiscal year ended December 31, 2025, showing a sequential revenue increase of 22% to 37% to $3.3 million–$3.7 million in Q4 2025 and a full‑year revenue of roughly $15 million, compared with $5.6 million in Q4 2024 and $32.1 million for the full year 2024. The sequential lift reflects stronger demand for the company’s B2B2C obesity‑management platform, while the year‑over‑year decline highlights the impact of a reduced product mix and the ongoing transition to a more focused commercial strategy.
Allurion’s operating expenses fell by about 50% in 2025, a reduction that narrowed the operating loss to $X (exact figure not disclosed) from $Y in the prior year. The cost‑control effort was driven by a disciplined hiring freeze, a shift to lower‑margin service contracts, and the elimination of non‑essential R&D spend. The tighter expense base, combined with the sequential revenue uptick, explains the narrower loss margin and signals that the company is moving toward a break‑even point as it scales its B2B2C model.
The company’s new commercial strategy, launched after a strategic pivot in 2025, is beginning to generate traction. Management highlighted that the strategy focuses on high‑margin, subscription‑based revenue from health‑tech partners and direct‑to‑consumer channels, which has helped offset the decline in legacy product sales. Allurion also continues to pursue a GLP‑1 combination therapy platform, with early‑stage data suggesting that pairing the Smart Capsule with GLP‑1s could broaden its market reach.
Allurion has made significant progress in the FDA’s pre‑market approval (PMA) process for its Smart Capsule. The company passed critical inspections and completed the Day‑100 meeting in late 2025, positioning the product for a potential approval in 2026. Management emphasized that the forthcoming FDA decision will be a key catalyst for the company’s growth trajectory and could unlock a new revenue stream that complements its existing obesity‑management services.
CEO Dr. Shantanu Gaur said, “We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter‑over‑quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold.” He added, “We have also continued to reduce our operating losses through a sharpening of our strategic focus, and, with that, I believe we have set ourselves up for an even more efficient 2026. With a potential FDA approval of our Allurion Smart Capsule on the horizon, I believe 2026 will be a historic year for Allurion.”
Allurion’s guidance for 2026 reflects confidence in the company’s cost‑control trajectory and the anticipated FDA approval. While specific revenue or margin targets were not disclosed in the preliminary release, management’s statements suggest an expectation of accelerated growth once the Smart Capsule enters the market and the B2B2C model scales further.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.